<DOC>
	<DOCNO>NCT00215748</DOCNO>
	<brief_summary>This study explore feasibility alternative dose dexamethasone pre-medication older breast lung cancer patient receive weekly docetaxel chemotherapy .</brief_summary>
	<brief_title>Reduced Dexamethasone Pre-Medication Dose Elderly Patients Receiving Weekly Docetaxel</brief_title>
	<detailed_description>Dose-limiting edema effusion associate cumulative docetaxel administraton necessitate recommendation patient premedicated oral corticosteroid dexamethasone prior docetaxel administration . Dexamethasone pre-medication may also decrease incidence severity acute hypersensitivity reaction associate docetaxel administration . However , administration weekly dexamethasone cause additional untoward side effect , especially old population . If data phase II study encouraging , study evaluate even low dose dexamethasone conduct .</detailed_description>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>age ≥ 65 year ; breast lung cancer patient receive docetaxel therapy per protocol ; corticosteroid administration , prescribe protocol , permit study participation , except topical administration adverse event ; performance status ECOG 02 ; peripheral neuropathy ≤ 1 ; adequate kidney liver function sign studyspecific inform consent Patients receive investigational drug within 4 week registration ; Prior concurrent malignancy ( surgically treat carcinoma situ ; Serious medical psychiatric illness would prevent informed consent ; Life expectancy &lt; 3 month ; Active uncontrolled bacterial , viral , fungal infection condition correct control .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Elderly</keyword>
	<keyword>Weekly</keyword>
</DOC>